With a White House-brokered deal, vaccine giant Merck has agreed to help Johnson & Johnson boost its COVID-19 vaccine production, which is woefully behind on its manufacturing schedule.
President Joe Biden announced today that, with the new deal, the country is on track to have enough COVID-19 vaccine doses to vaccinate every adult in the country by the end of May — two months ahead of earlier plans.
Merck—a powerhouse in vaccine production, responsible for the MMR (measles, mumps, and rubella) vaccine among others—will dedicate two US facilities to making the Johnson & Johnson COVID-19 vaccine. One facility will make the vaccine and the other will provide final-stage “fill and finish” services, involving aliquoting vaccine into vials and packaging them. The help from Merck stands to perhaps double J&J’s manufacturing.
Getting what can be done on time – accomplished early.